// App-Quantinova.ai

758 : Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

Researchers

Presenter

  • Kevin R. Kelly

Principal Investigators

  • Asher Chanan-Khan

  • George Somlo

  • Shailesh Chavan

  • Pankaj Patel

  • Markus Rothenburger

  • Andrea Wartenberg-Demand

  • Thomas Haeder

  • Kenneth C. Anderson

  • Leonard T Heffner

  • David S Siegel

  • Todd M Zimmerman

  • Sundar Jagannath

  • Nikhil C. Munshi

  • Sagar Lonial

  • Vivek Roy

  • Markus Ruehle

Medical Centers

  • Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA

  • Department of Radiology, University of Chicago, Chicago, IL

  • Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

  • Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Multiple Myeloma Program, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Hematology/Oncology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL

  • Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

Locations

  • United States

Companies

  • Biotest AG

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Multiple Myeloma

  • Hematological malignancies

  • Solid malignancies

  • Anemia

Biomarkers

  • Circulating tumor cells

  • Syndecan-1

Drug/Treatment

  • Indatuximab ravtansine

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

Outcome

  • N/A

Study Design

  • open label

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved